Title: Clinical-Immunological Profile of Myasthenia Gravis-A Tertiary Care Centre Experience
Authors: Chithra P, Thomas Iype, Bhagya S, Geetha S.
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.65
Abstract
Introduction: Myasthenia gravis (MG) is the commonest acquired autoimmune disorder of neuromuscular junction. Acetylcholine receptor antibodies are associated with MG, particularly generalized MG. There is some suggestion that MG in the Asian population may be clinically different from that in Caucasians There is a paucity of data on the clinical-immunological profile of myasthenia in the Indian population.
Methods: During a period of one year(September 2007 to August 2008), 32 consecutive patients of with a diagnosis of MG, presenting to the Neuromuscular clinic, Department of Neurology, at tertiary care referral were recruited for the study. All patients were followed up regularly for a minimum period of 3 years.
Objectives: To correlate the AChR antibody status and titer with clinical features of MG
Conclusion: AChR antibody are seen in high titer in generalized myasthenia than ocular myasthenia. The presence of higher AchR antibody titersis significantly associated with the presence of thymoma.
Keywords: Myasthenia Gravis, Antibodies, diagnosis, Thymoma.
References
1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26 (11):1054-9.
2. Aurangzeb S, Tariq M, Irshad M, Badshah M, Khan RS. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc. 2009;59(5):289-92.
3. Feng HY, Wang HY, Liu WB, He XT, Huang X, Luo CM, et al. The high frequency and clinical feature of seronegative myasthenia gravis in Southern China. Neurol Sci. 2013.
4. Gao F, Zhao X, Zhang J, Cui X, Zhang Y, Li Q, et al. Clinical features of patients with Myasthenia gravis from the Henan province, China. Muscle & nerve. 2016.
5. Chiu H, Vincent A, Newsom-Davis J, Hsieh K, Hung T. Myasthenia gravis Population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37(12):1854-.
6. Xu J, Yang M, Li B, Jiang H, Zhang R, Xu S. Myasthenia gravis: clinical study in 2385 patients. Chin J Neurol. 1999;32(6):347-50.
7. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai journal of medicine, New York. 1971;38(6):497.
8. Ashraf V, Taly A, Vasanth A, Veerendrakumar M, Rao S. Myasthenia Gravis: Clinical Spectrum And Long Term Follow-Up Study. Annals of Indian Academy of Neurology. 2005;8(1):7.
9. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol. 2013;20(2):309-14.
10. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of Myasthenia Gravis in Australia. Eur J Neurol. 2012;19(11):1413-20.
11. Bindu PS, Nirmala M, Patil SA, Taly AB. Myasthenia gravis and acetylcholine receptor antibodies: a clinico immunological correlative study on South Indian patients. Ann Indian Acad Neurol. 2008;11(4):242-4.
12. Vincent A, Newsom Davis J. Anti-acetylcholine receptor antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 1980;43(7):590-600.
13. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. Journal of Neurology, Neurosurgery & Psychiatry. 1985;48(12): 1246-52.
14. Soliven B, Lange D, Penn A, Younger D, Jaretzki Ar, Lovelace R, et al. Serone-gative myasthenia gravis. Neurology. 1988;38(4):514-.
15. Sanders DB, Andrews PI, Howard JF, Massey JM. Seronegative myasthenia gra-vis. Neurology. 1997;48(Suppl 5):40S-5S.
16. Limburg P, The T, Hummel-Tappel E, Oosterhuis H. Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 1. Relation to clinical parameters in 250 patients. Journal of the neurological sciences. 1983;58(3):357-70.
17. Compston D, Vincent A, Newsom-Davis J, Batchelor J. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103(3):579-601.
18. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, et al. Different characteristic phenotypes according to antibody in myasthenia gravis. J Clin Neuromuscul Dis. 2012;14(2):57-65.
19. Pasutharnchat N, Wacharapluesadee S, Hemachudha T. Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia gravis. J Med Assoc Thai. 2012;95(3):313-9.
20. Nikolic A, Djukic P, Basta I, Hajdukovic L, Stojanovic VR, Stevic Z, et al. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Clin Neurol Neurosurg. 2013;115(4):432-7.